IRWD - Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.
Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in total revenues in 2026 but faces 2027 Medicare price cuts and 2029 generic entry. Apraglutide's Phase 3 confirmatory trial launches in 2026, but competitive and regulatory hurdles cloud its $700m peak sales potential.
Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.14 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance. “Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-y.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (TPN) in the treatment of short bowel syndrome (SBS). Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of life, reduce line infections and lower the risk of thrombosis. The majority (46.4%) identified reducing the number of days per week on TPN as a priority attribute of future therapies. An additional 30.1% prioritized reducing TPN hours per day, while fewer respondents (11.3%) prioritized reducing TPN volume.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) f.
Small-cap stocks have outperformed amid a rotation away from mega caps, despite geopolitical uncertainty and shifting interest rate expectations. Small-cap firms may benefit from the next phase of AI adoption as productivity gains broaden across industries. Wells Fargo estimates that each 1% reduction in labor costs could translate into a 6.1% earnings increase for Russell 2000 companies.
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) Director Alexander Denner sold 6,730,800 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the transaction, the director directly owned 9,188,635 shares in the company, valued
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals is downgraded from a 'Buy' to a 'Sell' due to pipeline setbacks and declining LINZESS sales. IRWD declined to exercise its option on CNP-104 for PBC after disappointing data, removing a key pipeline catalyst. LINZESS U.S. sales dropped 6% to $864.5M in 2025, casting doubt on management's bullish 2026 sales guidance of $1.125–$1.175B.
Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.